State Street Corp Buys 1,895,529 Shares of Humacyte, Inc. (NASDAQ:HUMA)

State Street Corp boosted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 66.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,764,155 shares of the company’s stock after buying an additional 1,895,529 shares during the quarter. State Street Corp owned approximately 3.99% of Humacyte worth $25,917,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of HUMA. Millennium Management LLC boosted its stake in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC boosted its position in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares in the last quarter. Marshall Wace LLP grew its stake in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after buying an additional 450,031 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in shares of Humacyte during the second quarter worth approximately $1,550,000. Finally, AQR Capital Management LLC raised its stake in shares of Humacyte by 1,018.4% in the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Humacyte Stock Up 34.1 %

Shares of NASDAQ HUMA opened at $4.64 on Monday. Humacyte, Inc. has a 1 year low of $2.48 and a 1 year high of $9.97. The firm’s 50-day moving average is $4.83 and its 200-day moving average is $5.83. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $583.99 million, a PE ratio of -3.46 and a beta of 1.38.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on HUMA shares. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.43.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is currently owned by insiders.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.